Q-omics provides the consensus-scored STK11 profile across patient tissues and cancer cell-line models. STK11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, STK11 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, STK11 protein abundance shows 21,189 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, COAD, and GBM as cancer lineages where STK11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK11 survival associations across molecular data types. STK11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK11 RNA expression–survival associations across cancer types. High STK11 expression shows unfavorable associations in ACC, LGG and PRAD, but favorable associations in HNSC, UCEC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for STK11 RNA expression.
This table summarizes STK11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STK11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK11 shows higher tumor expression in COAD, LIHC, STAD, BLCA, HNSC and CHOL. The COAD box plot shows higher STK11 RNA expression in tumor versus normal tissue (log2 FC = +0.590, t-test p < 0.001).
This table shows molecular features associated with STK11 in patient tissues and cancer cell lines. In patient samples, STK11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STK11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
